哌柏西利联合来曲唑治疗晚期乳腺癌的总生存期
PALOMA-2研究在666例绝经后雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者中,按2:1随机分配至哌柏西利联合来曲唑组或安慰剂联合来曲唑组,中位随访90.1个月后,哌柏西利联合来曲唑组中位总生存期为53.9个月,安慰剂联合来曲唑组为51.2个月(HR 0.96,95%CI 0.78~1.18;分层单侧P=.34),总生存期未获显著改善。
要点
- 中位随访90.1个月,哌柏西利联合来曲唑组中位总生存期为53.9个月,安慰剂联合来曲唑组为51.2个月。
- 总生存期风险比HR为0.96(95%CI 0.78~1.18),分层单侧P=.34,未达统计学显著。
- 两组生存结局未知的患者比例分别为13.3%和21.2%,限制了总生存期结果的解读。
核心结论
- 与安慰剂联合来曲唑相比,哌柏西利联合来曲唑未显著改善雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者的总生存期。
研究设计与样本
- PALOMA-2研究纳入666例绝经后雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者,且未接受过晚期乳腺癌系统治疗,按2:1随机分配至哌柏西利联合来曲唑组或安慰剂联合来曲唑组。
主要发现
- 中位随访90.1个月时观察到405例死亡,已知存活155例。
- 哌柏西利联合来曲唑组中位总生存期为53.9个月(95%CI 49.8~60.8),安慰剂联合来曲唑组为51.2个月(95%CI 43.7~58.9),HR 0.96(95%CI 0.78~1.18),分层单侧P=.34。
- 两组生存结局未知的患者比例分别为13.3%和21.2%,这一失衡限制了总生存期结果的解读。
- 补充回收生存数据后,哌柏西利联合来曲唑组中位总生存期为53.8个月(95%CI 49.8~59.2),安慰剂联合来曲唑组为49.8个月(95%CI 42.3~56.4),HR 0.92(95%CI 0.76~1.12),单侧P=.21。
局限性
- 两组生存结局未知的患者比例失衡(13.3% vs 21.2%),限制了总生存期结果的解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.PALOMA-2 demonstrated statistically and clinically significant improvement in progression-free survival with palbociclib plus letrozole versus placebo plus letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC). Here, we report results for the secondary end point overall survival (OS). Postmenopausal women (N = 666) with ER+/HER2- ABC without previous systemic therapy for ABC were randomly assigned 2:1 to palbociclib plus letrozole or placebo plus letrozole. After a median follow-up of 90.1 months, 405 deaths were observed and 155 patients were known to be alive. The median OS was 53.9 months (95% CI, 49.8 to 60.8) with palbociclib plus letrozole versus 51.2 months (95% CI, 43.7 to 58.9) with placebo plus letrozole (hazard ratio [HR], 0.96 [95% CI, 0.78 to 1.18]; stratified one-sided P = .34). An imbalance in the number of patients with unknown survival outcome between the treatment arms (13.3% v 21.2%, respectively) limited interpretation of OS results. With recovered survival data, the median OS was 53.8 (95% CI, 49.8 to 59.2) versus 49.8 months (95% CI, 42.3 to 56.4), respectively (HR, 0.92 [95% CI, 0.76 to 1.12]; one-sided P = .21). OS was not significantly improved with palbociclib plus letrozole compared with placebo plus letrozole.
引用
- Slamon DJ, Diéras V, Rugo HS, et al. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. J Clin Oncol. 2024. PMID: 38252901. doi:10.1200/JCO.23.00137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。